导向综合治疗对肝癌耐药基因表达的影响  

EXPRESSION OF MULTIDRUG RESISTANCE GENE AFTER MULTIMODALITY TARGETING TREATMENT OF HEPATOCELLULAR CARCINOMA

作　　者：汤文英[1] 汤钊猷[1] 刘康达[1] 邹合强[1] 鲍卫华[1] 

机构地区：[1]上海医科大学肝癌研究所

出　　处：《上海医科大学学报》1995年第2期135-137,共3页Journal of Fudan University(Medical Science)

基　　金：中山医院中青年研究基金资助

摘　　要：用ＡＢＣ免疫组织化学方法（简称组化）对９２例肝细胞肝癌（ＨＣＣ）标本进行了耐 药基因产物 Ｐ－ＧＰ的检测。结果：术前未治疗的 ７６例 ＨＣＣ中，癌与癌周肝 Ｐ－ＧＰ组化染色 阳性率分别为６０．５％（４６／７６）与６９．７％（５３／７６）；由导向综合治疗后切除的１６例标本中其癌 与癌周肝分别为３１．２％（５／１６）与７８．３％（１１／１５）。表明经导向综合治疗后ＨＣＣ中Ｐ－ＧＰ的 表达显著低于来治疗组（Ｐ＜０．０５）。提示导向综合治疗有助于克服ＨＣＣ耐药。A total of 96 specimens of hepatocellular carcinoma (HCC) and its surrounding liver tissues were studied to assess the expression multidrug resistance (mdr) gene product P-glycoprotein (P-GP) in HCC. P-GP was evaluated by an immunopexoxidase detection system. Results: In 76 untreated cases, P-GP was detected in 60.5%(46/76) of HCC, and in 69.7%(53/76) of surrounding liver tissues. In multimodality targeting treatment group (n= 16), expression of P-GP was observed in only 31.2%(5/16) of HCC and in 73.3%(11/15) of surrounding liver tissues. Expresaion of P-CP in multimodality targeting treatment group statistically lower then thet of untreated group (P<0.05). The results indicate that by multimodality targeting treatment, such as radioimmunotherapy, might change multidrug resistance of HCC.

关 键 词：抗药基因 P-GP 导向综合治疗 肝肿瘤 癌 

分 类 号：R735.705[医药卫生—肿瘤]